EFFECT OF INTRAVENOUS ANTI-IL5 (MEPOLIZUMAB) IN HYPEREOSINOPHILIC SYNDROMES

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。该研究的目的是评估抗IL-5在18-24例嗜酸性粒细胞增多症（HES）患者中的安全性，并确定研究药物对嗜酸性粒细胞增多综合征（血液或组织中特定类型的白色血细胞数量高）的管理有什么影响（好或坏）。4组6人将接受抗IL-5。A组和B组为安全性组，在输注期间接受抗IL-5治疗，未改变其当前的HES药物。C组将接受药物治疗，而他们目前的羟乙基淀粉药物（泼尼松等）将在研究结束时减少25%。D组将遵循相同的做法，最多减少50%的当前HES药物。本研究的主要结局指标是该人群的安全性和外周血嗜酸性粒细胞水平和/或组织嗜酸性粒细胞水平的降低。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the study is to assess the safety of anti IL-5 in 18-24 patients with hypereosinophilia (HES) and determine what effect (good or bad) the study medication has on the management of hypereosinophilic syndromes (high number of a particular kind of white blood cell in the blood or in the tissues).¿ 4 groups of 6 individuals will receive Anti IL-5. Groups A and B are safety groups, receiving anti IL-5 with out changes to their current HES medications during infusions. Group C will receive the drug while their current HES medication ( prednisone, etc) would be reduced up to 25% by end of the study. Group D will follow do the same with up to 50% reduction in Current HES medication. Primary outcome measures for this study are safety in this population and reduction of Peripheral blood eosinophil levels and/ or tissue eosinophil level.